Vitamin D tests: how seasonal timing wastes your money

In the Northern Hemisphere, the usual pattern is a peak in August and a trough in February or March.

The difference is not trivial. Global epidemiological data indicate that vitamin D deficiency is approximately 1.7 to 2 times more prevalent in blood samples collected during winter and spring than in samples collected during summer and autumn. A test performed without recording the season can therefore create a false impression of persistent deficiency, or conceal a recurrent seasonal decline.

This is the central limitation of interpreting the vitamin D test: the result is real, but it may not represent the patient’s annual status.

The sinusoidal reality: vitamin D levels are not static

The relevant laboratory marker is serum 25(OH)D. It is the principal circulating storage form of vitamin D and the standard measurement used to assess vitamin D status. Its concentration reflects several inputs:

• cutaneous vitamin D synthesis from ultraviolet B exposure;
• dietary intake and fortified foods;
• supplementation;
• adipose storage and release;
• age-related changes in skin synthesis;
• body composition;
• liver and kidney conversion;
• absorption and medication effects.

These inputs do not remain constant. Sunlight exposure changes with latitude, season, clothing, outdoor activity, skin pigmentation, and local weather. Food intake may also shift during the year, although the seasonal effect of ultraviolet exposure is usually the dominant population-level driver.

The result is a broadly sinusoidal pattern rather than a stable plateau. Concentrations rise after the period of increasing solar exposure, reach a late-summer maximum, and then decline through autumn and winter. The curve is delayed relative to the solar stimulus. A patient does not reach the annual vitamin D maximum on the same day that solar radiation reaches its maximum.

A large United States analysis based on 3.44 million serum samples identified this pattern at population scale. The measured 25(OH)D concentration generally peaked in August and reached its lowest point in February or March. The seasonal response lagged the relevant solar exposure pattern by approximately eight weeks.

For a laboratory result, this creates a basic interpretive problem. Two tests from the same person can show materially different concentrations even when there has been no change in disease status. The difference may be produced by the calendar, not by a new pathological process.

What the number can and cannot establish

A result below 50 nmol/L, or below 20 ng/mL, is commonly used as the clinical threshold for vitamin D deficiency. Concentrations from 52.5 to 72.5 nmol/L, or 21 to 29 ng/mL, are often classified as insufficient. These categories are useful for clinical decision-making, but they do not eliminate the need for context.

A late-winter result below the deficiency threshold may indicate:

• a persistent year-round deficit;
• a predictable seasonal decline;
• inadequate dietary or supplemental intake;
• limited cutaneous synthesis;
• a combination of these factors.

The laboratory value alone cannot distinguish these mechanisms. Timing, treatment history, risk status, and previous measurements are required.

The same applies to a borderline result. A concentration just below or above a clinical cut-off should not be treated as a precise biological boundary. The analytical variation of the assay, biological variation, recent supplementation changes, and the month of sampling all affect interpretation.

A vitamin D test reports a concentration at one point in the seasonal cycle. It does not automatically report the patient’s annual vitamin D status.

The eight-week solar lag and the February nadir

The eight-week delay is a processing feature of human physiology, not a laboratory error. Solar exposure changes first. Cutaneous synthesis, transport, storage, utilization, and conversion then influence the circulating 25(OH)D pool over time.

This explains why the annual trough commonly occurs in February or March rather than immediately at the winter solstice. Solar airmass altitude is already increasing by then, but the circulating concentration still reflects the preceding months of low ultraviolet availability.

The same lag affects the timing of follow-up testing. A patient who changes the dose of a vitamin D supplement and returns to the laboratory after only a short interval may receive a result that does not represent the new maintenance state. Circulating 25(OH)D requires several weeks to approach a stable steady-state concentration after a dose change.

The practical sequence is therefore:

1. Identify the baseline condition. Record the month of testing, the current supplement dose, fortified food intake, and any relevant clinical risk factors.

2. Change the intervention if indicated. This may involve supplementation, dietary fortification, or investigation of absorption and medical causes.

3. Allow physiological stabilization. Testing immediately after the dose change can capture a transitional concentration rather than the eventual response.

4. Repeat under comparable conditions. A follow-up result is more useful when the laboratory method, supplement exposure, and season are known.

5. Interpret the result as a trend. The direction and magnitude of change matter more than a single borderline value.

The exact time needed to stabilize varies with the baseline concentration, dose, adherence, body composition, and clinical condition. There is no defensible universal interval that applies to every patient. The relevant point is narrower: testing too soon after changing supplementation can produce a misleading result.

Winter versus summer: the deficiency gap

Seasonal fluctuations in vitamin D levels produce a predictable shift in observed deficiency prevalence. Samples collected in winter and spring show deficiency approximately 1.7 to 2 times more often than samples collected in summer and autumn.

This does not mean that every individual becomes deficient during winter. It means that the probability of recording a concentration below the clinical threshold increases during the low-exposure part of the year.

Population health studies must therefore treat sample timing as a core variable. If one region collects most samples in February and another collects most samples in August, a direct comparison of deficiency prevalence may partly measure different points on the seasonal curve. The same problem appears in intervention studies, occupational health programs, and retrospective clinical datasets.

A prevalence estimate without sampling-season information is incomplete. At minimum, analysts need to know:

• the months included in the sample;
• the latitude and climate of the study population;
• whether the sample is population-based or clinically selected;
• the laboratory assay used;
• whether participants were taking vitamin D supplements;
• the age, skin pigmentation, body composition, and comorbidity profile of the cohort;
• whether the analysis adjusted for season.

The issue is particularly important when comparing demographic groups. Older adults may have lower cutaneous synthesis and less outdoor exposure. People with darker skin pigmentation generally require greater ultraviolet exposure to produce comparable amounts of vitamin D. Residents at higher latitudes experience a longer period of limited effective UVB exposure. These factors can interact with the calendar rather than operate independently of it.

A winter sample from an older, homebound cohort cannot be compared directly with a summer sample from a younger outdoor-working cohort and treated as evidence of a purely demographic difference. The sampling frame is measuring both population characteristics and exposure conditions.

Why seasonal adjustment is not cosmetic

Seasonal adjustment is sometimes treated as a statistical refinement. In vitamin D epidemiology, it can change the substantive conclusion.

Suppose a surveillance program measures 25(OH)D only during late winter. It may classify a large fraction of participants as deficient. If the same participants were measured near the annual peak, some would record higher concentrations without any intervention. That does not make the winter measurements invalid. It changes what they mean.

A winter value is useful when the question is whether concentrations fall below a clinically relevant threshold during the most vulnerable part of the year. It is less useful when the question is whether an asymptomatic, low-risk person has persistent year-round deficiency.

The correct interpretation depends on the operational objective:

The mathematics of year-round sufficiency

The late-summer result has a specific operational use. It can indicate whether the circulating 25(OH)D reserve is likely to remain above the sufficiency threshold during winter.

A late-summer or early-autumn concentration of approximately 60–80 nmol/L, equivalent to 24–32 ng/mL, is reported as the range needed to maintain a concentration above 50 nmol/L through the winter months without supplementation. This is not a guarantee for every individual. It is a seasonal reserve concept.

The result must be interpreted against the expected downward slope. A concentration of 55 nmol/L in August is not equivalent to 55 nmol/L in February. The August value is near the annual peak and may decline during the subsequent low-exposure period. The February value is near the annual trough and may rise as effective sunlight returns.

This distinction matters when evaluating food fortification. A fortified food product should not be assessed only by its ability to raise a summer concentration. The relevant endpoint is bioavailability yield across the low-exposure season. The fortification dose, food matrix, storage stability, processing losses, and habitual consumption pattern all contribute to the final serum response.

Industrial processing adds another layer. Vitamin D can be incorporated into a food matrix through premixing, liquid dosing, dry blending, or matrix encapsulation. Each approach produces a different exposure profile during production and storage. Degradation rates depend on temperature, oxygen, light, water activity, packaging, and contact with reactive components of the food.

A product may contain the declared amount at the point of manufacture but deliver a lower effective dose by the end of shelf life. That difference is relevant to population health programs because a small reduction in delivered dose may be amplified across months of low solar exposure.

The production assessment should therefore follow the entire chain:

1. Raw-material assay. Confirm the concentration and chemical form of the vitamin D ingredient.

2. Premix uniformity. Determine whether the vitamin is distributed consistently throughout the fortification blend.

3. Process survival. Measure losses during heating, extrusion, drying, homogenization, or other unit operations.

4. Storage stability. Quantify degradation rates under the intended packaging and shelf-life conditions.

5. Serving-level delivery. Calculate the actual vitamin D dose per habitual portion, not only per kilogram of product.

6. Bioavailability yield. Establish how much of the delivered vitamin becomes physiologically available after consumption.

7. Seasonal population effect. Model whether the intake is sufficient during the period when endogenous synthesis is limited.

Fortification policy fails when the calculation stops at the formulation tank. The consumer receives a processed product, not a nominal ingredient specification.

For vitamin D fortification, the relevant unit is not vitamin D added. It is stable, bioavailable vitamin D delivered through the low-sunlight season.

When to skip the laboratory visit

Routine population screening of asymptomatic, low-risk individuals is not recommended by major clinical guidance, including Choosing Wisely Canada and the Endocrine Society. The reason is not that vitamin D status is irrelevant. The problem is that indiscriminate testing creates borderline results that are difficult to interpret and may lead to unnecessary treatment adjustments or repeat laboratory expenditure.

A test is more defensible when there is a defined clinical or epidemiological question. Examples include a known risk of deficiency, conditions that impair absorption or metabolism, medication exposure that affects vitamin D handling, or monitoring after a clinically justified intervention.

The best month to check vitamin D depends on the question.

If the question is seasonal vulnerability

Late winter, commonly February or March in the Northern Hemisphere, is the most informative period for observing the annual nadir. A low result at this time identifies the concentration during the season of greatest physiological pressure.

It should not, by itself, be described as proof of chronic year-round deficiency in an asymptomatic healthy person. That conclusion requires additional evidence.

If the question is maintenance through winter

Late summer to early autumn provides a more useful reserve assessment. A concentration around 60–80 nmol/L at this stage is associated with a greater likelihood of remaining above 50 nmol/L through winter without supplementation. The estimate remains individual-dependent.

If the question is response to supplementation

Do not treat an early post-intervention result as a stable endpoint. The circulating marker needs several weeks to respond to a changed dose. The test should be scheduled according to the clinical purpose and expected steady-state period, not simply the first available appointment.

If the question is population prevalence

Use a sampling protocol that accounts for calendar month. Options include:

• collecting samples evenly across the year;
• reporting prevalence separately by season;
• applying a validated seasonal adjustment;
• using repeated measurements in a defined cohort;
• standardizing laboratory methods and clinical thresholds.

Without this control, a surveillance system can mistake seasonal amplitude for a change in population health.

The cost of poor timing

The financial waste from poorly timed vitamin D testing is not limited to the price of the blood draw. A borderline winter value can trigger a sequence of low-yield actions: repeat testing, unscheduled supplement changes, additional consultations, and interpretation of results that were never comparable in the first place.

The cost-benefit calculation is straightforward:

• Testing a low-risk asymptomatic population: low interpretive yield and high potential for borderline findings.
• Testing a defined high-risk patient: higher clinical value because the result answers a specific management question.
• Testing at the seasonal nadir: useful for assessing winter vulnerability, but unsuitable as automatic proof of chronic deficiency.
• Testing near the late-summer peak: useful for assessing reserve, particularly when the objective is year-round sufficiency.
• Repeating a test too soon after supplementation changes: poor value because the measured concentration may not represent the new steady state.
• Comparing results from different seasons without adjustment: technically possible, analytically weak.

The correct protocol is not to select one universal month and apply it to every patient. It is to define the question first, record the seasonal position, and then choose the sampling window that answers that question.

Final position

Vitamin D test seasonal variation accuracy depends less on the laboratory instrument than on the sampling design. Serum 25(OH)D follows a reproducible annual pattern, with a late-summer peak, a February–March nadir, and an approximately eight-week lag behind the solar cycle. Winter and spring samples show deficiency much more often than summer and autumn samples.

A single result is therefore a time-stamped measurement, not a complete diagnosis. For low-risk asymptomatic individuals, routine screening can create more ambiguity than information. For patients with defined risk factors, testing is more useful when the month, supplement exposure, and time since dose adjustment are documented.

From a population-health and food-fortification perspective, the target is not a high summer value. The target is stable delivery and adequate bioavailability during the months when cutaneous synthesis is constrained. That requires seasonal epidemiology, controlled testing protocols, and production systems that measure degradation rates through the full shelf life.

The practical conclusion is strict: test for a defined reason, record the season, allow supplementation changes to stabilize, and never interpret a winter concentration as a year-round diagnosis without supporting evidence.